Citius Oncology launched LYMPHIR™ for cutaneous T-cell lymphoma treatment, showcasing early adoption in oncology centers.
Mar 31, 2026
United StatesBiotechnologyHealth CareMedicalTherapeuticsPharmaceuticalBiopharma
Product Description
Citius Oncology provided a commercial update on the U.S. launch of LYMPHIR™, highlighting early adoption across leading oncology centers and broad payer coverage.
Company Information
Company
Citius Oncology
Location
United States
About
Citius Oncology, Inc. is a Delaware-based clinical-stage biopharmaceutical company focused on developing innovative therapies for the treatment of cancer. The company specializes in the development of novel cancer treatments, including targeted therapies and immunotherapies, designed to improve the effectiveness and safety of cancer care. Citius Oncology operates primarily in the United States and is listed on The Nasdaq Capital Market under the ticker symbol CTOR. The company's strategic focus includes advancing its pipeline of therapies through clinical trials, positioning itself to address unmet medical needs in oncology, and catering to the growing demand for effective cancer treatments.
Fundz sees it the moment Citius Oncology ships something new, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
United StatesBiotechnologyHealth CareMedicalTherapeuticsPharmaceuticalBiopharma